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This study evaluated the effect of co-administration of extracts of Vernonia amygdalina Del. (VA) and 
Azadirachta indica Linn.(AI) on haemapoietic and immunological indices of normal and diabetic rats. 
White blood cells which were non-significantly decreased (p>0.05) in diabetic control rats relative to the 
normal control, respectively increased and decreased non-significantly (p>0.05) upon administration of 
the combined extracts of VA and AI to diabetic and non-diabetic test rats. Packed cell volume, 
haemoglobin content and red cell count as well as its derived factors (mean cell volume, mean cell 
haemoglobin and mean cell haemoglobin concentration) of both diabetic and non-diabetic rats were not 
affected by the treatment, relative to their respective controls. As compared to insulin treatment, the 
combined extracts significantly increased (p<0.05) mean cell haemoglobin concentration (MCHC) of 
diabetic rats. Platelets number which was non-significantly lower (p>0.05) in diabetic control rats as 
compared to non-diabetic control was further decreased non-significantly (p>0.05) upon administration 
of the combined extracts and insulin. Diabetes induction significantly increased CD4
+ count (p<0.05) as 
compared to the normal control. This was however decreased significantly (p<0.05) upon treatment with 
the combined extracts and insulin. The combined extract similarly decreased CD4
+ counts in normal test 
rats as compared to the normal control. Combined extracts of VA and AI is non-haematotoxic and may 
possess some anti-inflammatory properties when used as a management against diabetes mellitus.  
 





Since ancient times, plants have been exemplary source 
of medicine (Grover et al., 2002) and have played key 
roles in traditional health care systems and also form the 
basis of a significant percentage of allopathic and modern 
drugs in industrialised nations of the world (Calson, 1998; 
Samy and Gopalakrishnakone, 2007). In Africa alone, up 
to 80% of the population uses traditional medicine for 
primary healthcare, whereas in industrialised parts of the 
world its counterpart or adaptations also exist in various 
forms called Complementary and Alternative Medicine 
(CAM) (WHO, 2003). The World Health Organisation 
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traditional medicine strategy in 2002 to assist countries 
develop national policies on evaluation and regulation; 
create a stronger evidence base on safety, efficacy and 
quality; ensure availability and affordability; promote 
therapeutically sound use; and document them especially 
in diseases including HIV/AIDS, malaria, sickle cell 
anaemia and diabetes mellitus (WHO, 2003). 
In line with the aforementioned, numerous herbs have 
not just been screened for their hypoglycaemic and 
antihyperglycaemic activities, but have gained approval 
of several cooperate bodies and organisations to be 
further researched into. The believe is that medicinal 
preparations either from a single herb or a combination of 
herbs are holistic in therapeutic approach and may be 
best suited for a syndrome such as diabetes with multiple 
pathologies (Tiwari and Rao, 2002). More so,  they  could  




Table 1. Experimental design. 
 
Group Number of animal Treatment 
Non-diabetic batch   
NC 6 Placebo (non diabetic control ) 
NVA 6 V. amygdalina extract (200 mg/kg b.w) 
NAI 6 A. indica extract (200 mg/kg b.w) 
NVA/AI 6 V. amygdalina and A. indica combined extracts (100 mg/kg b.w each) 
NHU 6 Insulin (5 unit/kg b.w) 
   
Diabetic batch   
DC 6 Placebo (diabetic control ) 
DVA 6 V. amygdalina extract (200 mg/kg b.w) 
DAI 6 A. indica extract (200 mg/kg b.w) 
DVA/AI 6 V. amygdalina and A. indica combined extracts (100 mg/kg b.w each) 




be better dietary adjuncts in the establishment and main-
tenance of euglycemia since plant foods are thought to 
have acquired biological adaptations to the human 
system, hence have minimal side effects (Srinivasan, 
2005). 
The comparative antidiabetic activity of two plants used 
in traditional management of diabetes: Vernonia 
amygdalina Del. and Azardirachta indica A. Juss, was 
recently investigated in our laboratory (Ebong et al., 
2006). Later, enhanced efficacy in glycaemic control and 
reduced toxicity effect of combined extracts from the two 
plants and individual extracts in alloxan diabetic rat 
models was reported (Ebong et al., 2008). In furtherance 
of these previous reports, we in this investigation 
evaluated the effect of combined extracts of these plants 
(V. amygdalina and A. Indica) on haematological and 
immunological indices of normal and streptozotocin 
diabetic rats, with a view to ascertain the effect of the 
potential anti-diabetic option on complications of 
haemapoietic and immune systems usually engendered 
by chronic diabetes mellitus.  
 
 
MATERIALS AND METHODS 
 
Collection of plant materials 
 
Matured leaves of V. amygdalina (Del.) and A. indica (A. Juss) were 
respectively collected from the Endocrine Research Farm and the 
Staff Village, University of Calabar. These were duly authenticated 
and voucher specimens were deposited in a herbarium (ERU/ 
2006/011 and ERU/2006/012, respectively) in the Department of 
Botany. The leaves were rinsed severally with clean tap water to 
remove dust particles and debris and thereafter allowed to 
completely drain.  
 
 
Preparation of plant extracts 
 
The plant materials were separately chopped with a knife on a 
chopping board and (1 kg) each of A. indica and V. amygdalina was 
homogenized with an electric blender in 1.95 and 2.25 L of 80% 
(v/v) ethanol, respectively. The mixtures were then allowed for 48 h 
in a refrigerator at 4°C for thorough extraction of the plants’ active 
components. These were then filtered with cheesecloth and later 
with Whatman No. 1 filter paper to obtain a homogenous filtrate. 
The filtrates were then concentrated in vacuo at low temperature 
(37 to 40°C) to about one tenth of the original volume using a rotary 
evaporator. The concentrates were further allowed open in a water 
bath (40°C) for complete dryness yielding 40.54 g (4.054%) and 
34.71 g (3.471%) of greenish brown and brown oily substances for 
V. amygdalina and A. indica, respectively. The extracts were then 
refrigerated at 2 to 8°C until use. 
 
 
Animals and experimental design 
 
60 male albino rats of Wistar strain weighing about 140 to 180 g 
were obtained from the animal house of the Department of Zoology 
and Environmental Biology, University of Calabar, Calabar. The 
animals were allowed to acclimatize for three weeks in the animal 
house of the Department of Biochemistry during which they were 
housed in well ventilated cages (wooden bottom and wire mesh 
top) and kept under controlled environmental conditions of 
temperature (25 ± 5°C), relative humidity (50 ± 5%) and 12 h 
light/dark cycle. The 60 rats were divided into five parallel groups 
consisting of a diabetic and a non-diabetic batch, each with six 
animals per group (Table 1).  
 
 
Induction of experimental diabetes 
 
Prior to diabetes induction, the rats were subjected to 12 h fast, and 
then diabetes was induced by intraperitoneal injection of 65 mg/kg 
b.w. with streptozotocin (STZ) (Sigma St. Louis, MO, U.S.A). 
Control animals received saline only. Seven days after STZ 
treatment, diabetes was confirmed in STZ treated rats with a fasting 
blood sugar concentration 200 mg/dl. This was estimated using 
One Touch ® Glucometer (Lifescan, Inc. 1995 Milpas, California, 





Diabetic and non-diabetic animals were grouped as shown in Table 
1 and accordingly, treated with extracts and insulin. The dosages of  





















































































































































the plant extracts were as determined from preliminary work in our 
laboratory, whereas insulin dose, NPH (5 U/kg b.w. s.c.) was as 
previously used by Sonia and Srinivasan (1999). The plant extracts 
were administered via gastric intubation, twice per day (6.00 am 
and 6.00 pm) and insulin once per day post prandial (6.00 pm) for 
28 days. The animals were maintained on pelletised growers mash 
(obtained from Vital Feeds, Jos, Plateau State, Nigeria) and tap 
water. Both the feed and water were provided ad libitum and 
environmental conditions maintained as stated earlier throughout 
the 28 days. 
 
 
Collection of samples for analysis 
 
At the end of the 28 days, food was withdrawn from the rats and 
they were fasted overnight but had free access to water. They were 
then euthanized under chloroform vapour and sacrificed. Whole 
blood was collected via cardiac puncture using sterile syringes and 
needles. The whole blood was emptied into EDTA containers 
preparatory to CD4+ and haematological (full blood count) analysis. 
 
 
Full blood count assays  
 
Full blood counts including PCV, Hb, RBC, WBC, platelet count, 
differential WBC (lymphocytes and mixed), and red cell indices 
(MCHC, MCH and MCV), were estimated using the Sysmsex® 
Automated Haematology Analyzer KX-21N, Sysmex Corporation, 
Kobe-Japan. The pre-diluted (PD) sample method was used where 
blood was diluted manually, and then fed into the transducers. The 
transducer chamber has a minute hole called the aperture. On both 
sides of the aperture, there are electrodes between which flows 
direct current. Blood cells suspended in the diluted sample pass 
through the aperture, causing direct current resistance to change 
between the electrodes. As direct current changes, the blood cell 
size is detected as electric pulses. Blood cell count is then 
calculated by counting the pulses, and a histogram of blood cell 
sizes is plotted by determining the pulse sizes. Also, analyzing a 
histogram makes it possible to obtain various analysis data 






The CD4+ lymphocytes were estimated using the Cyflow Automated  
Cell Counter (Partec, Germany). 10 µl of CD4+ PE antibody (Partec, 
Germany) was mixed with 50 ml of EDTA anticoagulated whole 
blood in a test tube. The mixture was incubated in the dark 
chamber for 15 min at room temperature of 22 to 28°C. During 
incubation, the content of the tube was mixed every 5 min. 800 µl of 
buffer solution was added, mixed and plugged into the counter. The 






The results were analysed for statistical significance by one way 
ANOVA using the SPSS statistical program and Post Hoc Test 
(LSD) between groups, using MS excel program. All data were 






Presented in Tables 2 and 3 are the haematological and 
immunological indices of non diabetic and diabetic rats, 
respectively, that received various treatments for 28 
days. White blood cells (WBC) which were non-signifi-
cantly decreased (p>0.05) in diabetic control rats relative 
to the normal control, became increased non-significantly 
(p>0.05) upon administration of the extracts of VA only, 
combination of VA and AI, and insulin as compared to the 
diabetic control. Similar treatments in the non-diabetic 
rats rather produced a non significant reduction (p>0.05) 
in WBC relative to the non-diabetic control. Red blood 
counts (RBC), haemoglobin (HB) content, packed cell 
volume (PCV) and their derived factors-mean cell volume 
(MCV), mean cell haemoglobin (MCH) and mean cell 
haemoglobin concentration (MCHC) of both diabetic and 
non-diabetic test groups were not affected by the different 
treatments, except for AI extract which significantly 
increased (p<0.05) HB in diabetic test rats and MCV in 
non diabetic test rats when respectively compared to 
insulin treated and non diabetic control groups. Also, 
MCHC levels of diabetic test rats treated with extracts of 










































































































































































VA alone, and VA and AI combined together were 
significantly higher (p < 0.05) than insulin administered 
group. Platelet counts in diabetic rat were non-
significantly lower than the normal control rats. Whereas 
administration of VA and AI extracts singly caused 
increased platelet number, combined extracts and insulin 
treatments showed further decreases. However, these 
changes were non significant (p>0.05). Besides, AI 
extract treatment which caused significant decrease 
(p<0.05) in platelets as compared to the combined 
extracts and insulin in non-diabetic rats, other test groups 
showed non significant changes. There was significant 
increase in CD4
+ counts (p<0.05) of diabetic rats relative 
to non-diabetic rats. These were significantly decreased 
in all diabetic test groups (p<0.05). In non-diabetic test 
groups also, CD4
+ levels was significantly decrease 
(p<0.05) following treatments with the extracts of VA, AI 
alone, and VA and AI combined together, relative to the 
non diabetic control. The decrease in insulin treated 





Anaemia in diabetes, atherosclerosis resulting from 
increased platelet aggregation, glycosylation of haemo-
globin (RBC) and of recent, white blood cells, are some 
terms discussed extensively in diabetes (Colwell and 
Nesto, 2003; Thomas et al., 2005; Nakagami et al., 2005; 
Yamagishi et al., 2005. We therefore assayed in our 
study, haemapoietic status and some immune system 
indices.  
WBC, RBC and PCV were seen to be decreased in the 
untreated diabetic rats as compared to the non-diabetic. 
These could result from onset of glycosylation process in 
the untreated diabetic rats or ensuing anaemia of 
diabetes. Anaemia has been identified as a common 
complication of chronic kidney disease (CKD), affecting 
over half of all patients (USRDS, 2002) and the most 
common cause of CKD in about 2/3 of cases is diabetes 
mellitus (Thomas et al., 2005). These authors in an 
earlier study indicated that approximately 7% of patients 
with diabetes had haemoglobin level less than 11 g/dl 
(Thomas et al., 1998). Though the diabetic subjects in 
this investigation were rats, our report of 10.85 ± 0.63 g/dl 
haemoglobin level is in accordance with these authors’ 
findings. This was reflected also in PCV and RBC as 
would be expected. The non significance in these 
differences could be attributed to the duration of the study 
(28 days). This period may have been too short for 
pronounced pathogenesis required for full expression of 
anaemia– glycosylation or advanced glycosylation end 
products AGEs formation and end stage damage of 
kidney to impair erythropoietin synthesis or formation. 
Our observation as per VA extracts contrast Oboh 
(2001), who had reported decreased RBC and PCV, due 
to induced haemolysis in normal rats treated with saponin 
extracts from VA leaves. When used as whole extracts, 
other constituents in the leaves of VA or AI used in 
combination, may have interacted synergistically to 
suppress the haemolytic effects of the saponins. The 
observed slight reduction in WBC in AI extract treated 
rats both in diabetic and non-diabetic rats does not imply 
reduced immunity since the result of the lymphocyte 
count compared well with that of the non-diabetic control 
rats. According to Leob (1991), WBC count may vary by 
as much as 2,000 due to strenuous exercise, stress or 
digestion and is diagnostically useful only when 
interpreted in light of the white cell differential count.  
Platelet counts appeared to have decreased slightly in 
the diabetic control relative to the non-diabetic. Thrombo-
cytopenia is usually seen as destruction caused by drugs 
or immune disorders. There appear to be an immune 
disorder  from   our  study,  as  seen  clearly  in  the  CD4
+  




counts and the decrease in platelet counts. Also, 
decrease in circulating platelet number may also mean 
an increase in aggregated platelet typical of athero-
sclerotic disorders including diabetes mellitus. Increased 
platelet activation and subsequent aggregation favouring 
thrombosis has been extensively discussed (Colwell and 
Nesto, 2003; Brand et al., 1998). Prostacyclin and nitric 
oxide which inhibit this process in normal endothelium 
are reportedly reduced in people with diabetes (Klein and 
colwell, 1996; Martina et al., 1998). The observed 
increase with VA extract treatment in diabetic and non-
diabetic rats may be connected with decrease in aggre-
gability engendered by the antioxidant property of the 
plant. Platelets from diabetics have been reported to 
contain reduced antioxidant levels (Sarji et al, 1979). It is 
not clear however why the observation was not similar 
with AI extract and combined extracts of VA and AI.  
The elevated CD4
+count in diabetic controls as 
compared to non-diabetic control observed in this study is 
a probable inflammatory response to atherosclerotic 
pathogenesis of diabetes. Blood-borne immune cells 
constitute an important part of atheroma, the core of 
which is infiltrated by T-cells and predominantly the CD4
+ 
T cells (Hansson, 2005). Metabolic breakdown in 
diabetes usually results in increased circulation and 
deposition of lipids in arteries; atherosclerosis (Hansson, 
2005), hence an increase in immune and inflammatory 
response which eventually leads to elevation in 
associated T-cell variant, CD4
+. Reduction in CD4
+ counts 
by administration of extracts of AI and VA singly and in 
combination would not be unconnected with their anti-
inflammatory effects. The anti inflammatory properties of 
AI (Biswas et al., 2002) and VA (Farombi, 2003) have 
extensively been reviewed. These effects were also 
demonstrated in non-diabetic rats as opposed to insulin. 
In conclusion, administration of the extracts of VA and AI 
singly and in combination may therefore be more potent 
as anti inflammatory agents than insulin in the 
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